[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Southern California\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":717},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,111,0,25,[9,49,75,110,136,162,188,218,240,259,281,307,327,358,381,403,431,452,479,498,523,541,566,583,600],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053214","braincraving-response-to-smoking-cues-after-oral-nicotine-pouch-use-100053214",false,"NCT07698470","Brain\u002FCraving Response to Smoking Cues After Oral Nicotine Pouch Use","Cue-Exposure Response Evaluation: Brain Reactivity to ONPs","Inclusion Criteria:\n\n* Age 21 years - 55 years\n* Self-reported use of cigarettes within the past 30 days\n* Biochemical confirmation of cigarette use:\n\n  o Carbon monoxide (CO) breath sample ≥10 ppm\n* Fagerström Test for Nicotine Dependence (FTND) score ≥5, indicating moderate to high nicotine dependence\n* Fluent in English\n* Willing to try an oral nicotine pouch\n* Willing to abstain from nicotine for at least 12 hours prior to each experimental session\n\nExclusion Criteria:\n\n* Age younger than 21 years or older than 55 years\n* Biochemical evidence inconsistent with recent cigarette use:\n\n  o CO breath sample \\\u003C10 ppm\n* Expressed intent to reduce or quit nicotine use within the next 30 days\n* History of medical conditions contraindicated for nicotine use (e.g., uncontrolled hypertension, recent cardiac events)\n* Primary use of non-cigarette products (e.g., cigars, pipe tobacco, smokeless tobacco)\n* Prior use of oral nicotine products in their lifetime",true,"ALL","21 Years","55 Years",{"count":22,"type":23},45,"ESTIMATED","INTERVENTIONAL",[26],"NA","Oral nicotine pouches (ONPs) are non-combustible nicotine products that may reduce cigarette craving and smoking cue-induced brain activity, supporting their potential as harm-reduction tools for adults who smoke cigarettes. This within-subject, repeated-measures study will evaluate the acute effects of a single 6 mg oral nicotine pouch on subjective craving and prefrontal neural responses to smoking-related cues using functional near-infrared spectroscopy (fNIRS). Participants will complete assessments before and after nicotine pouch administration following overnight nicotine abstinence to characterize changes in craving and neural cue reactivity.",[29],"Nicotine Dependence",[31,32,33,34,35],"Oral Nicotine Pouches","Oral Nicotine Products","Smoking","Cigarettes","Harm Reduction","RECRUITING","2026-07-07",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2026-04-30",{"date":44,"type":23},"2027-08",{"name":46,"class":47},"University of Southern California","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100542391","phase-1-coes-curing-order-effects-on-sealants-100542391","NCT06342258","COES: Curing Order Effects on Sealants","Effects of Cured Bond On Sealant Retention In The Pediatric Population","COES","Inclusion Criteria:\n\n* ASA I and ASA II children, aged 5 to 14 years who are patients of CDHC and USC with adequate eruption of permanent first or second molars for placement of sealants\n* These teeth will not have previous restorations, interproximal lesions, pathology, or occlusal lesions.\n* Behavior of the children should be within a Frankl 3 or 4 category, indicating a \"positive\" and \"Definitely Positive\" behavior rating, which would allow for safe and controlled execution of the proposed protocol\n* Patient must have contralateral molars in the same arch in which sealants can be placed. For example a child with #30 and #19 present will qualify for the study.\n\nExclusion Criteria\n\n* Any tooth with previous sealant placement\n* Children who are allergic or intolerant to sealant material\n* Children who cannot tolerate a dental suction isolation system, such as DryShield isolation\n* Children who do not complete a prophy cup polish.\n* Children who present with banded or bracketed molars\n* Patients or Parents who cannot fully understand an English or Spanish Consent\u002F Assent form.\n\nWithdrawal Criteria\n\n* Patients can withdraw voluntarily at any time.\n* Any tooth which has progression of caries beyond ICCMS Category 3 will be withdrawn from the study. These teeth will be treated with appropriate restorative dental treatment according to the standard of care.\n* Any qualifying tooth that subsequently requires a restoration due to trauma will be withdrawn from the study.\n* Any patient with an adverse reaction to treatment will be withdrawn. This event will be reported to the IRB.","5 Years","14 Years",{"count":60,"type":23},217,[62],"PHASE1","Background: Sealants are a great tool in the prevention of caries in the pediatric population. It has been shown that up to 71% of occlusal decay is preventable after a single sealant application in a fissure, and thus is the standard of care due to difficulty for pediatric patients in hygiene, diet, and overall home care until manual dexterity increases.\n\nPurpose: This prospective randomized case control study aims to look at the longevity of sealants with bonding agent cured prior to sealant placement vs those with uncured bond. The study will be performed by USC graduate pediatric personnel.\n\nMethods: A split mouth prospective randomized control study will be performed on pediatric dental patients at Long Beach Memorial's Children's Dental Health Clinic and USC Pediatric Dental Clinic, placing sealants with cured bond on half of a mouth and sealants with uncured bond on the contralateral half. Intraoral photos will be obtained at the initial visit and recalls to evaluate the overall retention\u002Flongevity of the sealant placement. The goal of this study is determine which sealant has higher longevity and to provide recommendations for future pediatric dentists regarding sealant procedures.",[65,66],"Dental Sealant","Sealant Retention","2026-06-29",{"date":69,"type":40},"2026-07-02",{"date":71,"type":40},"2024-02-23",{"date":73,"type":23},"2027-06",{"name":46,"class":47},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":24,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100611717","mapt-protocol-fixation-versus-arthroplasty-surgical-treatments-for-early-recovery-after-hip-fracture-faster-hip-100611717","NCT07244211","MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)","Musculoskeletal Adaptive Platform Trial (MAPT): Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)","FASTER-HIP","Inclusion Criteria:\n\n* 60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture\n* The patient has a health condition affecting physical mobility.\n* Complete fracture of the femoral neck (AO\u002FOTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging.\n* Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction.\n* Low energy injury mechanism.\n* Surgeons with expertise in internal fixation and total hip arthroplasty or hemiarthroplasty are available to perform surgery.\n\nExclusion Criteria:\n\n* The patient is not clinically suitable for either compared treatment.\n* Expected injury survival of less than 12 months.\n* Terminal illness with expected survival of less than 12 months.\n* Incarceration.\n* Unable to obtain informed consent due to language barriers.\n* Unable to obtain informed consent because the legally authorized representative was unavailable.\n* Problems, in the judgment of the study personnel, with maintaining follow-up with the patient.\n* Currently enrolled in a study or intervention domain that does not permit co-enrollment.\n* Prior enrollment in the specific platform trial intervention domain.\n* Patient or legally authorized representative did not provide informed consent (declined participation).\n* Eligible patient or legally authorized representative was not approached within the screening window (missed participant).\n* Other reasons to exclude the patient, as approved by the data coordinating center.\n* Associated lower extremity injury that prevents post-operative weight-bearing.\n* Retained hardware around the hip that precludes either study treatment.\n* Infection around the hip (soft tissue or bone).\n* Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.\n* Injury did not occur within 21 days of screening.\n* Patient is too ill, in the judgment of the attending surgeon, for internal fixation.\n* Patient is too ill, in the judgment of the attending surgeon, for arthroplasty.","60 Years",{"count":85,"type":23},600,[26],"This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.",[89],"Femoral Neck Fractures",[91,92,93,94,95,96,97,98,99,100],"Minimally displaced femoral neck fractures","arthroplasty","hip fractures","femoral fractures","orthopaedic procedures","older adults","patient-centered outcomes","adaptive trial","internal fixation","pragmatic trial","2026-06-19",{"date":103,"type":40},"2026-06-24",{"date":105,"type":40},"2026-01-23",{"date":107,"type":23},"2030-01-31",{"name":46,"class":47},15,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":17,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":48},"100641353","cochlear-implantation-and-social-outcomes-100641353","NCT07584837","Cochlear Implantation and Social Outcomes","Inclusion Criteria:\n\n* Age \\>= 60 years\n* English or Spanish speaking\n* older adults with bilateral moderate to profound sensorineural hearing loss who are candidates for cochlear implants or have undergone cochlear implantation.\n\nExclusion Criteria:\n\n* Age \\\u003C60 years\n* Unable to complete questionnaires in English or Spanish",{"count":117,"type":23},40,"OBSERVATIONAL","The goal of this clinical trial is to learn if hearing devices, like cochlear implants, affect social and cognitive function of older adults. The main questions the researchers want to answer are:\n\n* How social are older adults with hearing loss before and after using hearing devices?\n* How well do older adults with hearing loss think before and after using hearing devices?\n* For older adults who have hearing loss and use hearing devices, do changes in social interaction explain changes in how well they think (cognitive function)?\n* Do brainwaves (EEGs) in older adults with hearing loss change after using hearing devices?\n* Are there differences in how social older adults with hearing loss are compared to older adults without hearing loss?\n\nWhat Participants Will Do:\n\n* Participants will take questionnaires for around 60 minutes. Questionnaires will ask participants about their background, health, hearing, and how social they are. Another set of questionnaires will check their thinking ability or cognition.\n* Participants will wear an audio sensor (TILES Audio Recorder on Jelly Mobile phone) for 2 weeks. The sensor will collect and store information about a participant's voice during conversations. Once the device has information about a participant's voice such as pitch and tone it will store this information and delete the audio recording. Words spoken during conversations will be deleted.\n* (Optional) Participants can choose to participate in a 45-60-minute EEG (electroencephalogram) recording session. Participants will have sensors placed on top of their heads. Sensors will record the participants' brainwaves. Sounds will be played to see how participants' brainwaves change when they hear sounds. Eligible participants will be invited to participate in 4-month follow-up study.",[121],"Hearing Loss, Bilateral Sensorineural",[123,124,125,126],"hearing loss","cochlear implant","social engagement","cognition","NOT_YET_RECRUITING","2026-06-17",{"date":130,"type":40},"2026-06-22",{"date":132,"type":23},"2027-07-01",{"date":134,"type":23},"2030-12-31",{"name":46,"class":47},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":17,"sex":18,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":24,"phases":146,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":48},"100575593","evaluating-telehealth-delivery-of-brief-alcohol-screening-and-intervention-for-college-students-100575593","NCT06774300","Evaluating Telehealth Delivery of Brief Alcohol Screening and Intervention for College Students","Tele-BASICS","Inclusion Criteria:\n\n* between 18 and 26 years of age\n* fluent in understanding English\n* a registered student at one of the two intervention sites\n* adequate internet capabilities to support video-conferencing\n* access to a webcam, which is a standard features of most laptops, mobile devices, and desktops\n* engage in binge drinking (i.e., 4 or more standard drinks in a sitting for women or 5 or more standard drinks in a sitting for men) at least once in the past month (for the volunteer sample only)\n* experienced at least one negative alcohol-related consequence in the previous month (mandated students would meet this due to receiving an alcohol sanction)\n* reports a score of 2 or higher on questions about a) interest in reducing their drinking, or b) interest in not increasing their drinking.\n\nExclusion Criteria:\n\n* not meeting inclusion criteria or unwillingness to participate","18 Years","26 Years",{"count":85,"type":23},[26],"This research study will test the efficacy of a telehealth version of the Brief Alcohol Screening and Intervention for College Students (BASICS), which is the gold standard prevention and intervention approach to target heavy alcohol use on college campuses across the United States.",[149],"Alcohol Consumption",[151,152,153,154],"alcohol","drinking","brief intervention","teleheath","2026-06-15",{"date":128,"type":40},{"date":158,"type":40},"2025-09-01",{"date":160,"type":23},"2030-07-31",{"name":46,"class":47},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":24,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":48},"100456946","sensory-optimization-of-the-hospital-environment-100456946","NCT05230199","Sensory Optimization of the Hospital Environment","Multisensory Interventions to Improve Neurodevelopmental Outcomes of Preterm Infants Hospitalized in the Neonatal Intensive Care Unit","SOOTHE","Inclusion Criteria:\n\n* ≤ 32 weeks estimated gestational age (EGA)\n* recruited within the first week of life\n\nExclusion Criteria:\n\n* \\> 32 weeks EGA at birth\n* \\>7 days old\n* become wards of the state\n* have a suspected or confirmed congenital anomaly\n* face a high immediate threat of death, per the opinion of the attending physician.","1 Day","7 Days",{"count":173,"type":23},215,[26],"The long-term goal of this project is to improve the health and well-being of preterm infants and their parents. Although there is evidence to support positive multisensory interventions in the NICU, these interventions are often applied in an inconsistent manner, reducing their benefit. Through a rigorous and scientific process, we have developed a structured multisensory intervention program, titled Supporting and Enhancing NICU Sensory Experiences (SENSE), which includes specific doses and targeted timing of evidence-based interventions such as massage, auditory exposure, rocking, holding, and skin-to-skin care. The interventions are based on the infant's developmental stage and are adapted based on the infant's medical status and behavioral cues. The multisensory interventions are designed to be conducted during each day of NICU hospitalization by the parents, who are educated and supported to provide them. The proposed work aims to determine the effect of multisensory interventions on parent mental health, parent-child interaction, brain activity (amplitude integrated electroencephalography), and infant developmental outcomes through age 2 years, with specific attention to language outcome.",[177,178,179,180,181],"Preterm","Parent-Child Relations","Parents","Development, Infant","Sensory Integration Dysfunction",{"date":128,"type":40},{"date":184,"type":40},"2023-05-29",{"date":186,"type":23},"2028-12-31",{"name":46,"class":47},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":17,"sex":18,"minAge":143,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":24,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":48},"100641098","early-intervention-to-prevent-development-of-ptsd-in-burn-survivors-and-their-caregivers-100641098","NCT07656545","Early Intervention to Prevent Development of PTSD in Burn Survivors and Their Caregivers","Inclusion Criteria:\n\n* Alert, oriented, \\& not withdrawing from substance at time of screening\n* Can read and write in English\n* Hospitalized within 10 days of burn injury\n* Anticipated discharge \\\u003C=4 weeks\n* Have an email, mailing address, and at least 1 smart device for telehealth sessions\n* PTSD risk score of 2 or greater (patient-only)\n* Willing to attend therapy sessions with a loved one\n\nExclusion Criteria:\n\n* Currently incarcerated or in police custody\n* \\> 10 days post-burn\n* Lifetime diagnosis of primary psychosis or intellectual disability\n* Ongoing reported domestic violence in the dyad\n* Unstable bipolar disorder, severe substance use disorder, or acute suicidality with imminent intent that does not remit within 10 days of burn-injury\n* Inflammation Confounds (patient-only) of BMI \\> 40, metabolic syndrome, admission A1C of \\>= 6.5%\n* Currently receiving couples therapy",{"count":195,"type":23},44,[26],"The purpose of this clinical trial is to adapt and test a brief patient-caregiver early intervention designed to reduce posttraumatic stress symptoms in hospitalized burn patients and their caregivers. This intervention is a brief, 4-session cognitive-behavioral intervention designed for burn patients and their loved one to complete together, during and after hospitalization. The intervention targets relational communication and functioning through reduction of invalidating, negative statements and avoidant coping by teaching patients and their loved ones to engage in adaptive natural disclosures, supportive responses, and approach coping after the burn trauma. The intervention uses evidence-based psychotherapy techniques, including psychoeducation, motivational interviewing, and skills coaching. The clinical trial will occur in two sequential phases. In the first phase of the study (case series), the intervention will be provided to two burn patient-caregiver dyads (four adults) to pilot test the intervention, seek patient and provider feedback, and refine the intervention. All four adults will receive the intervention. In the second phase of the study, the randomized controlled trial (RCT) phase, investigators will enroll 20 more burn patient-caregiver dyads (40 more adults) who will be randomly assigned (like the flip of a coin) at the dyad level to receive the intervention or a burn survivor-only minimally enhanced usual care psychoeducation control condition (mEUC). The goals of the RCT phase are to study whether the intervention is acceptable to patients, feasible to conduct, and whether the intervention improves burn survivor-caregiver healthy relationship communication about difficult events and treatment outcomes compared to mEUC.",[199,200,201,202,203,204,205,206,207,208,209],"Posttraumatic Stress Disorder","Burns","Traumatic Injury","Acute Stress Disorder","Trauma and Stressor Related Disorders","Trauma and Stress Related Disorders","Stress Disorder","Stress Disorders, Post-Traumatic","Stress Disorders, Traumatic","Stress Disorders, Traumatic, Acute","Relationship, Social","2026-06-14",{"date":212,"type":40},"2026-06-18",{"date":214,"type":23},"2026-08-01",{"date":216,"type":23},"2029-02-28",{"name":46,"class":47},{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":17,"sex":18,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":24,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":48},"100641145","impact-of-risk-feedback-on-behavioral-trajectories-100641145","NCT07657221","Impact of Risk Feedback on Behavioral Trajectories","Alcohol Metabolism and Disease Risk in Asians: Examining the Impact of Personalized Phenotypic\u002FGenotypic Feedback on Early Drinking Trajectories","Inclusion Criteria:\n\n* USC student of Chinese, Japanese, Korean, or Vietnamese heritage\n\nExclusion Criteria:\n\n* not a USC student, not 17-25 years old, not of Chinese, Japanese, Korean, or Vietnamese heritage","17 Years","25 Years",{"count":228,"type":23},450,[26],"The goal of this study is to examine the effects of providing personalized information about behavioral, physical, and genetic factors that are associated with elevations in risk for some health problems. The main research question is: can we affect young adult behaviors through communication about these health-related risks? Participants will be asked to complete an in-person baseline session where they provide a DNA sample, complete online surveys, and do a brief interview. They will then receive one of several brief online information sessions and be followed in online surveys approximately every 3 months over the next 2 years.",[232,149],"Healthy","2026-06-12",{"date":212,"type":40},{"date":236,"type":23},"2026-08-18",{"date":238,"type":23},"2030-08-31",{"name":46,"class":47},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":246,"minAge":143,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":255,"leadSponsor":257,"locationsCount":258},"100614436","gyn-aide-gynecologic-oncology-navigation-through-ai-driven-education-100614436","NCT07279571","GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education","AI-chatbot Evaluation (Aim 1):\n\nInclusion Criteria:\n\n* Patient of the LA General gynecologic oncology clinic\n* Age 18 years or older\n* Previously obtained the HPV vaccination (initial chatbot evaluation)\n* Eligible for HPV vaccination (pilot intervention; age \\\u003C46)\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Patients who do not speak English or Spanish\n* Patients who do not provide informed consent\n\nHPV vaccination rate (Aim 2):\n\nInclusion Criteria:\n\n* Patient of the LA General gynecologic oncology clinic\n* Age 18 years or older\n* Obtained the HPV vaccine\n\nExclusion Criteria:\n\n* None","FEMALE",{"count":248,"type":23},48,"This study seeks to understand how endometrial cancer patients get medical information about cancer care and their satisfaction with those health-seeking methods. It also assesses patient interest in using an artificial intelligence educational resource.",[251],"Endometrial Carcinoma",{"date":253,"type":40},"2026-06-16",{"date":233,"type":40},{"date":256,"type":23},"2028-06-09",{"name":46,"class":47},2,{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":246,"minAge":143,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":24,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":48},"100642254","energy-deficiency-on-hormones-in-contraceptive-users-100642254","NCT07651800","Energy Deficiency on Hormones in Contraceptive Users","Effects of a Modest Energy Deficit on Reproductive Hormones Across the Menstrual Cycle in Contraceptive Users","Inclusion Criteria:\n\n* Female, aged 18-35 years\n* Recreationally active (engaging in structured exercise between 8-15 hours per week)\n* BMI of 18.5-29.9 as a BMI below or above these cut points results in highly varied menstrual cycle lengths17\n* Not currently experiencing an eating disorder or disordered eating, or having a diagnosed eating disorder in the last 3 years\n* Non-pregnant or planning to become pregnant\n* Medically free from chronic diseases\n* Currently using one of the following contraceptive methods for ≥3 months:\n\nMonophasic oral contraceptive\n\n* Hormonal intrauterine device (H-IUD)\n* Copper intrauterine device\n* Weight stable (no weight change \\>5% body weight within the past 3 months)\n* Weight greater than or equal to 110 lbs\n* Not suffering from known gynecological disease (i.e., PCOS, endometriosis, etc.) that may influence menstrual cycle regularity\n* Willing and able to maintain current exercise habits throughout the study\n* Willing to follow study dietary guidance to achieve a \\~250 kcal\u002Fday energy deficit during Cycle 2\n\nExclusion Criteria:\n\n* Amenorrhea or oligomenorrhea\n* Perimenopausal or menopausal\n* Currently pregnant, planning pregnancy, or breastfeeding\n* Use of hormonal contraception other than monophasic oral contraceptives or hormonal IUD (implant, nuvaring, etc.)\n* Initiation or change of contraceptive method within the past 3 months\n* Diagnosis of polycystic ovary syndrome (PCOS), endometriosis, hypothalamic amenorrhea, or other known reproductive endocrine disorder\n* Current or history of eating disorder or clinically diagnosed disordered eating\n* Current participation in intentional weight loss or weight gain program\n* Use of medications known to affect metabolism or hormone levels (e.g., systemic corticosteroids, thyroid medications, insulin, GLP-1 agonists)\n* Known metabolic, cardiovascular, renal, hepatic, or endocrine disease\n* Musculoskeletal injury limiting exercise participation within the past 3 months\n* Smoking or nicotine use\n* Contraindications to DXA scanning (e.g., pregnancy, recent high-radiation diagnostic imaging exceeding institutional limits)\n* Inability or unwillingness to comply with study procedures","35 Years",{"count":268,"type":23},30,[26],"The purpose of the present study is to characterize the endocrine and metabolic responses to a modest, short-term energy deficiency (\\~250 kcal\u002Fday) across the menstrual cycle in recreationally active women using different contraceptive methods (oral contraceptive, hormonal IUD, and non-hormonal IUD). This study will leverage daily urinary hormone metabolite tracking and comprehensive metabolic assessments, providing foundational data addressing an important and previously unexamined interaction between energy availability and hormonal regulation in contraceptive users.",[272,273],"Energy Deficiency Due to Short-term Fasting","Hormonal Contraception","2026-06-10",{"date":253,"type":40},{"date":277,"type":23},"2026-09",{"date":279,"type":23},"2027-12",{"name":46,"class":47},{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":18,"minAge":143,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":24,"phases":290,"briefSummary":291,"conditions":292,"keywords":298,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":258},"100514906","personalized-health-self-management-training-for-colorectal-cancer-survivors-100514906","NCT05984589","Personalized Health Self-Management Training for Colorectal Cancer Survivors","A Prospective, Randomized, Controlled, Double-Arm Study of RISE (Re-Invent, Integrate, Strengthen, Expand) Personalized Self-Management Training (PSMT) Compared to Standardized Self-Management Training (SSMT) in Gastrointestinal Cancer (GI) Patients","Inclusion Criteria:\n\n* Age ≥18 years at the time of consent.\n* History of Stage I-IV colorectal cancer (CRC) or other gastrointestinal cancer within the past 10 years prior to enrollment.\n* Ability to speak, write, and read English sufficiently to allow for program participation.\n* Identified by self-report as having willingness and interest to work on at least one lifestyle-related risk factor. Lifestyle-related risk factors include diet, physical activity, body composition, alcohol use.\n* Scoring ≤3.5 on the World Cancer Research Fund\u002FAmerican Institute for Cancer Research (WCRF\u002FAICR) Health Behavior Adherence Scale or in the low-to-moderate range in any subcategory consistent with moderate to low adherence to healthy behavior recommendations (HBRs).\n* Ambulatory and independent in activities of daily living (ADL).\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Cognitive or mental impairments that in the opinion of the Principal Investigator or study physician would hinder the program participation.",{"count":289,"type":23},120,[26],"This is a Phase 2 prospective, randomized, controlled, double-arm study to assess personalized self-management training (PSMT) intervention efficacy and patient experiences compared to standardized self-management training (SSMT). A total of 120 gastrointestinal (GI) cancer patients will be enrolled and randomized 1:1 to complete a 6-week self-management training program (either PSMT or SSMT) to be carried out by licensed occupational therapists with doctoral training.\n\nThis study aims to examine whether PSMT is more effective in increasing adherence to healthy behavior recommendations compared to SSMT in GI cancer patients.",[293,294,295,296,297],"Colorectal Cancer","Healthy Lifestyle","Behavior, Health","Health Behavior","Gastrointestinal Cancers",[299],"self-management training","2026-06-08",{"date":274,"type":40},{"date":303,"type":40},"2024-03-01",{"date":305,"type":23},"2028-11-30",{"name":46,"class":47},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":18,"minAge":143,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":24,"phases":316,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":48},"100626066","personalized-ai-driven-models-in-cognitive-behavioral-therapy-for-anxiety-100626066","NCT07430800","Personalized AI-Driven Models in Cognitive Behavioral Therapy for Anxiety","SCH: Personalized AI-Driven Models for Supporting User Engagement and Adherence in Health Interventions: Validation in Cognitive Behavioral Therapy for Anxiety","Inclusion Criteria:\n\n* Are 18 years of age or older\n* Are university students\n* Are able to communicate in English\n* Have corrected-to-normal vision and hearing\n* Consent to have audio\u002Fvideo\u002Finteraction data recorded as part of the study\n* Have a GAD-7 (Generalized Anxiety Disorder-7 item) score of 5 or greater, indicating mild to elevated levels of self-reported symptoms of anxiety\n* Have a lower than minimal level of suicidality risk as measured by the Columbia Suicide Severity Rating Scale (C-SSRS) during screening (\"NO\" responses to items 3, 4, 5, and 6 on C-SSRS)\n* Having access to home WiFi\n\nExclusion Criteria:\n\n* Are less than 18 years of age\n* Are not university students\n* Are not able to communicate in English\n* Do not have corrected-to-normal vision and hearing\n* Do not consent to have audio\u002Fvideo\u002Finteraction data recorded as part of the study\n* Have a GAD-7 (Generalized Anxiety Disorder-7 item) score of 4 or lower.\n* Higher than a minimal level of suicidality risk as measured by the Columbia Suicide Severity Rating Scale (C-SSRS) during screening (\"YES\" responses to items 3, 4, 5, or 6 on C-SSRS)\n* Don't have access to home WiFi",{"count":315,"type":23},140,[26],"Untreated anxiety undermines long-term physical and emotional wellbeing, especially among college students, with rates worsening since the onset of the COVID-19 pandemic. Cognitive Behavioral Therapy (CBT) is the leading evidence-based intervention for anxiety, but many students fail to complete exercises between CBT sessions, reducing its effectiveness. Socially assistive robots (SARs) help promote adherence to home-based practice in the context of elder care, social skill learning, and physical therapy, but it is unknown how SARs can enhance CBT. The specific objective of this research is to develop personalized CBT SARs that can support CBT compliance for college students with anxiety. To meet the goals of the proposed work, these studies will determine how SAR personalization based on implicit and explicit feedback can help promote greater CBT compliance and anxiety reduction outcomes for students.",[319],"Generalized Anxiety Disorder (GAD)","2026-06-04",{"date":300,"type":40},{"date":323,"type":40},"2026-03-30",{"date":325,"type":23},"2028-08-15",{"name":46,"class":47},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":18,"minAge":335,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":24,"phases":339,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":48},"100505899","using-indoor-air-filtration-to-slow-atherothrombosis-progression-in-adults-with-ischemic-heart-disease-history-100505899","NCT05867381","Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History","Slowing Atherothrombosis Progression Through Indoor Air Filtration: A Crossover Trial in Hispanic and Non-Hispanic Adults With Ischemic Heart Disease History","SAPIA","Inclusion Criteria:\n\n* Age between 65 and 84 years old;\n* Weight ≥ 110 pounds;\n* Nonsmokers for at least 1 year;\n* Have ischemic heart disease history, clinically stable for 6 months, without any deterioration in symptoms or episodes of angina based on past electronic medical records;\n* Both English and Spanish speaking participants will be included in the recruitment;\n* Live in the Los Angeles County.\n\nExclusion Criteria:\n\n* Have history of degenerative disease of the nervous system such as dementia and Alzheimer's;\n* Currently have active cancer treatments;\n* The residential house has already had HEPA filters;\n* Participants will move out from the current residential address in the next 2 years;\n* Participants will spend more than 1 month living outside the primary home;\n* Have any health conditions that prohibit collecting health and covariate data and biospecimens;\n* Participants' residential houses are not feasible for setting up air purifiers and air pollutants monitors.","65 Years","84 Years",{"count":338,"type":23},112,[26],"This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.",[342,343],"Air Pollution","Atherosclerosis",[345,346,347,348,343,349,350,351],"Air pollution","Particulate matter","Air purifier","HEPA filter","Ischemic Heart Disease","Thrombosis","Cardiovascular Disease",{"date":300,"type":40},{"date":354,"type":40},"2023-07-11",{"date":356,"type":23},"2028-06-30",{"name":46,"class":47},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":246,"minAge":143,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":24,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":48},"100538932","manual-lymphatic-drainage-breast-massage-in-breast-cancer-patients-after-breast-conserving-surgery-100538932","NCT06297265","Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery","Feasibility and Effects of Manual Lymphatic Drainage (MLD) Breast Massage in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy","Inclusion Criteria:\n\n* Female with native breasts and localized breast cancer who are status post-lumpectomy surgery, will receive whole breast radiation therapy with\u002Fwithout nodal irradiation, with standard fractionation or moderate hypofractionation\n* Age \\>= 18 years\n* Ability to understand and the willingness to sign a written informed consent in English or Spanish\n\nExclusion Criteria:\n\n* Underlying diagnosis of chronic inflammatory illness or collagen vascular disorder, e.g. scleroderma, lupus, rheumatoid arthritis, fibromyalgia as these conditions may significantly affect the likelihood and magnitude of radiation related toxicity\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Inability to provide written informed consent in English or Spanish\n* Patients receiving ultra-hypofractionation, and\u002For partial breast or chest wall radiation therapy are excluded",{"count":366,"type":23},50,[26],"This phase II trial evaluates manual lymphatic drainage breast massage for reducing treatment-related side effects in women undergoing radiation therapy after breast conserving surgery for breast cancer that has not spread to other parts of the body (localized). Breast conserving surgery can be an effective treatment option for early stage breast cancer, but it can also be associated with side effects including fluid collection in tissues\u002Fswelling (lymphedema), pain, reduced quality of life, and poorer body image. Manual lymphatic drainage is a gentle massage technique used to reduce swelling. It may be a safe and effective way to reduce treatment-related side effects in women receiving radiation therapy after surgery for localized breast cancer.",[370,371,372],"Anatomic Stage 0 Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Localized Breast Carcinoma","2026-06-03",{"date":375,"type":40},"2026-06-05",{"date":377,"type":40},"2024-05-24",{"date":379,"type":23},"2027-12-31",{"name":46,"class":47},{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":18,"minAge":143,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":24,"phases":390,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":402},"100351619","low-dose-radiotherapy-in-treating-painful-bone-metastases-in-patients-with-multiple-myeloma-100351619","NCT03858205","Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma","Phase II Multi-Institutional Study of Low-Dose (2Gy) Palliative Radiotherapy in the Treatment of Symptomatic Bone Metastases From Multiple Myeloma","Inclusion Criteria:\n\n* Histologic diagnosis of multiple myeloma\n* Painful bone metastasis (index lesion) that has a radiographic correlate\n* Patient may have had any number of prior chemotherapy\u002Fimmunotherapy regimens (changes to systemic therapy or use of bisphosphonates for 4 weeks before and after RT are allowed, but recording of these changes must be made so it can be accounted for)\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* Brief Pain Inventory (BPI) score \\>= 2\n* Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Patients will be ineligible if the index lesion has received prior radiation therapy or prior palliative surgery. Patients may have received prior palliative or primary radiotherapy or surgery to other parts of the body, as long as the index lesion was not in the prior radiation fields and has not received prior palliative surgery\n* Patients will also be ineligible if there is pathologic fracture or impending fracture at the site of the index lesion or planned surgical fixation of the bone at the index lesion\n* Patients with clinical or radiographic evidence of spinal cord or cauda equina compression\u002Feffacement from the index lesion, and\u002For with index lesions located at the skull base or orbital lesions\n* Patients must not be pregnant",{"count":389,"type":23},100,[26],"This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.",[393,394,395],"Bone Pain","Metastatic Malignant Neoplasm in the Bone","Plasma Cell Myeloma",{"date":375,"type":40},{"date":398,"type":40},"2019-03-11",{"date":400,"type":23},"2027-03-11",{"name":46,"class":47},9,{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":18,"minAge":410,"maxAge":411,"enrollmentInfo":412,"targetDuration":4,"studyType":24,"phases":414,"briefSummary":415,"conditions":416,"keywords":418,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":427,"completionDateStruct":428,"leadSponsor":430,"locationsCount":4},"100638251","home-and-community-use-of-a-suspension-walker-in-pre-walking-infants-with-down-syndrome-100638251","NCT07631130","Home and Community Use of a Suspension Walker in Pre-Walking Infants With Down Syndrome","Feasibility of a Novel Overground Stepping Intervention for Pre-Walking Infants With Down Syndrome","Inclusion Criteria:\n\n* Diagnosis of Down syndrome\n* 10-13 months of age\n* Able to sit independently\n* Unable to walk independently\n\nExclusion Criteria:\n\n* Medical or orthopedic conditions other than Down syndrome that prevent standing or walking","10 Months","13 Months",{"count":413,"type":23},12,[26],"The goal of this clinical trial is to learn if pre-walking infants with Down syndrome can use a suspension walker in their home and community environments. The main questions it aims to answer are:\n\n* Is suspension walker intervention feasible for pre-walking infants with Down syndrome?\n* What are barriers to successfully using suspension walkers in home and community environments?\n* What are facilitators for successfully using suspension walkers in home and community environments?\n\nParticipants will:\n\n* Use a suspension walker in the home and community for a three-month period (goal 20 minutes\u002Fday, 5 days\u002Fweek)\n* Meet with a therapist three times in their home to learn how to use the walker\n* Track how often they use the walker for one week each month\n* Complete assessments of infants' gross motor skill and ability to use the walker before and after the three-month period\n* Be interviewed after the three-month period about their experiences using the walker",[417],"Down Syndrome",[419,420,421,422,423,424],"Down syndrome","infant","mobility device","walker","walking","early intervention","2026-06-02",{"date":375,"type":40},{"date":277,"type":23},{"date":429,"type":23},"2028-08",{"name":46,"class":47},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":246,"minAge":143,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":24,"phases":440,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":48},"100569963","phase-4-evaluation-of-a-long-versus-short-clomid-protocol-for-controlled-ovarian-stimulation-100569963","NCT06701071","Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation","Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation in Patients With Diminished Ovarian Reserve Undergoing In-vitro Fertilization: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Undergoing IVF\n* Must meet POSEIDON criteria based on clinic evaluation\n* Female partner: Antral follicle count of 2 or more and age \\\u003C45 at time of stimulation start\n* Male partner\u002Fsperm source: Cannot be azoospermic\n* Planning freeze-all cycle (regardless of blastocyst or cleavage stage culture) or fresh transfer if randomized to short Clomid group\n* Planning 36-hour trigger window\n\nExclusion Criteria:\n\n* Normal ovarian reserve or good response\n* Allergy or adverse reaction to Clomid\n* Minimal stimulation protocols\n* History of prior premature ovulation","45 Years",{"count":289,"type":23},[441],"PHASE4","The goal of this clinical trial is to evaluate a long Clomid protocol as compared to a 5-day Clomid protocol for ovarian stimulation in patients with diminished ovarian reserve undergoing ovarian stimulation for in-vitro fertilization. The aim of the long Clomid protocol is to intensify stimulation of the ovaries and reduce both cost and injection burden for patients. Participants will be randomized to receive the long Clomid protocol vs. the typical protocol involving Clomid only for 5 days followed by growth hormone-releasing hormone (GnRH) antagonist. The primary outcome the investigators will evaluate will be the number of mature eggs retrieved.",[444],"Infertility, Female","2026-06-01",{"date":373,"type":40},{"date":448,"type":40},"2025-06-01",{"date":450,"type":23},"2028-06",{"name":46,"class":47},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":18,"minAge":459,"maxAge":225,"enrollmentInfo":460,"targetDuration":4,"studyType":24,"phases":462,"briefSummary":463,"conditions":464,"keywords":467,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":4},"100640642","an-online-intervention-to-reduce-e-cigarette-use-and-cigarette-smoking-risk-in-adolescents-100640642","NCT07624292","An Online Intervention to Reduce E-cigarette Use and Cigarette Smoking Risk in Adolescents","An Online Intervention to Reduce E-cigarette Use and Potential for Cigarette Smoking in Adolescents","Inclusion Criteria:\n\n* be between the ages of 12 to 17\n* be able to read English\n* be a current resident of California\n* report vaping at least one day per week in the past month\n* report no history of cigarette use at screening and baseline\n* have access to a computer or mobile device with internet access\n\nExclusion Criteria:\n\n* currently receiving nicotine cessation services","12 Years",{"count":461,"type":23},150,[26],"The goal of this clinical trial is to learn if a brief digital intervention can reduce e-cigarette use and prevent cigarette smoking initiation in teenagers ages 12-17. The main questions it aims to answer are:\n\n* Compared to the control condition, does the intervention reduce e-cigarette use frequency in teenagers?\n* Compared to the control condition, does the intervention reduce risk to start smoking cigarettes in teenagers? Researchers will compare the digital intervention to see if it leads to greater reductions in e-cigarette use and smoking risk than a waitlist control condition.\n\nParticipants will complete 5 brief online surveys across 12 weeks, and some will be selected to do a post-intervention virtual interview. In this interview, participants will be asked to share their opinions about the intervention and identify areas that need refinement.",[465,466],"E-cigarette Use","Cigarette Smoking Risk",[468,469,470,471],"E-cigarette","Tobacco","Nicotine addiction","mHealth","2026-05-31",{"date":373,"type":40},{"date":475,"type":23},"2026-07-01",{"date":477,"type":23},"2027-03-30",{"name":46,"class":47},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":17,"sex":246,"minAge":485,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":258},"100598796","breast-cancer-screening-adherence-for-women-at-moderate-risk-for-breast-cancer-100598796","NCT07076147","Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer","Inclusion Criteria:\n\n* \\* \\>= 30 years\n\n  * =\\\u003C 75 years\n  * Women with either:\n\n    * Genetic test results showing moderately increased breast cancer risk due to a pathogenic\u002Flikely pathogenic variant in ATM, CHEK2, BARD1, RAD51C, or RAD51D (Mutation carrier group) OR\n    * Calculated lifetime breast cancer risk estimates between 20% and 40% according to the Tyrer-Cuzick V8.0B empiric risk model (Empiric risk group)\n  * Patients provided breast cancer risk assessments by genetic counselors at USC Norris or LA General Hospital beginning in 2021 and at least 12 months ago\n  * Women recommended to undergo annual breast MRI and\u002For annual mammogram beginning at the time of their genetic counseling risk assessment\n  * English or Spanish speaking patients\n\nExclusion Criteria:\n\n* \\* History of breast cancer before genetic counseling at University of Southern California (USC)\n\n  * Any metastatic cancer diagnosis at time of genetic counseling risk assessment\n  * Deceased\n  * Patient underwent a risk reducing mastectomy before their genetic counseling risk assessment","30 Years","75 Years",{"count":461,"type":23},"This study assesses breast cancer screening adherence for women at moderately increased risk for developing breast cancer based on gene mutation status or empiric risk model estimates. It also seeks to determine facilitators and barriers to screening.",[490],"Breast Carcinoma","2026-05-29",{"date":445,"type":40},{"date":494,"type":40},"2025-06-02",{"date":496,"type":23},"2028-06-02",{"name":46,"class":47},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":506,"minAge":20,"maxAge":507,"enrollmentInfo":508,"targetDuration":4,"studyType":24,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":522,"locationsCount":258},"100554521","golf-recreational-exercise-for-enhanced-survivorship-in-prostate-cancer-survivors-100554521","NCT06500169","Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors","Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors Undergoing Hormone Therapy (GREENS)","GREENS","Inclusion Criteria:\n\n* First time, primary diagnosis of prostate cancer (PCa)\n* Currently receiving androgen deprivation therapy (ADT) and\u002For androgen receptor blocker) for more than 6 months\n* Older adult male: 55-85 years old\n* The ability to stand independently without external support\n* No or minimal golf experience (played \\\u003C 5 times in the past 10 years)\n* English speaking\n\nExclusion Criteria:\n\n* Second cancer diagnosis (excluding non-invasive skin cancers) or bone metastases\n* Prostatectomy less than 6 months prior to study enrollment (prostatectomy is not a requirement for study entry)\n* Symptomatic cardiovascular disease, active angina, uncontrolled hypertension (systolic blood pressure (SBP) \\> 160 or diastolic blood pressure (DBP) \\> 90, high resting pulse heart rate (HR) \\> 90), symptomatic orthostatic hypotension\n* Unstable asthma, exacerbated chronic obstructive pulmonary disease (COPD\\]\n* History of injury or orthopedic operation within the last 6 months\n* Movement disorders (e.g., Parkinson's disease (PD) or other neurological disorders), hemiparesis or paraparesis\n* Severe vision or hearing problems","MALE","85 Years",{"count":509,"type":23},20,[26],"This clinical trial evaluates a golf recreational exercise program for enhancing survivorship in underrepresented prostate cancer survivors. Golf is a multimodal recreational activity that requires participants to utilize all muscle groups to perform the golf swing, walk over hilly and uneven terrain, maintain balance during putting and squat-like tasks. Physical activity and exercise are beneficial to physical function, cognitive function, psychosocial health, and overall quality of life during prostate cancer survivorship. These aspects of health are impacted by prostate cancer treatment, especially androgen deprivation therapy. Additionally, supervised, group-based activity programs facilitate participation in physical activity. Researchers want to examine the changes in functional abilities, psychosocial health, and quality of life following participation in in a golf program designed for prostate cancer survivors.",[513,514,515,516,517],"Localized Prostate Carcinoma","Locally Advanced Prostate Carcinoma","Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8","Stage II Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8",{"date":373,"type":40},{"date":520,"type":40},"2023-09-01",{"date":379,"type":23},{"name":46,"class":47},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":18,"minAge":143,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":24,"phases":531,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":258},"100521004","confronting-cancer-as-a-community-100521004","NCT06063928","Confronting Cancer as a Community","Inclusion Criteria:\n\n* Self-reported Hispanic ethnicity\n* Diagnosed with colon or rectal cancer (at any time and stage; lifetime diagnosis and in survival are eligible)\n* Has a tumor tissue sample archived or plans to have tissue archived from a standard care procedure\n* Age \\>= 18 years\n* Ability to understand and the willingness to sign a written informed consent.\n* For those who would like to participate in the optional microbiome characterization aspect of the study, the patient will have to be under 40 years old at any clinical cancer stage or over 60 years old at any clinical cancer stage.\n\nExclusion Criteria:\n\n* Inability to understand and the willingness to sign a written informed consent",{"count":530,"type":23},500,[26],"This study aims to better understand the cause of colorectal cancer and how to find the best treatment for Hispanic patients with colorectal cancer. The genetic information in the blood and tissues may explain why patients who have the same type of cancer and receive the same treatment do not always have the same results. By combining genetic (certain qualities or traits passed from parents to offspring) information with clinical data, such as the responses of different kinds of cancers to different treatments, this study could lead to more knowledge about why certain cancers occur and why they respond differently to treatments. Information gathered from this study may help researchers match treatments to the genetics of each patient and the genetic changes in their tumor. This approach is known as personalized medicine.",[534],"Colorectal Carcinoma",{"date":425,"type":40},{"date":537,"type":40},"2022-05-25",{"date":539,"type":23},"2028-05-25",{"name":46,"class":47},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":18,"minAge":143,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":24,"phases":550,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":560,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":258},"100500068","phase-1-au409-for-the-treatment-of-advanced-primary-liver-cancers-or-solid-tumor-with-liver-metastatic-disease-100500068","NCT05791448","AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease","First in Human Dose Escalation Study of AU409 in Patients With Advanced Primary Liver Cancers or Advanced Solid Tumor With Liver Predominant Metastatic Disease","Inclusion Criteria:\n\n* Age \\>= 18 years old\n* Patients must have histopathologically \u002Fcytologically confirmed advanced solid tumor, which is refractory to standard therapeutic options, or for which there are no standard therapeutic options. Failure of all approved therapies that have a marginal impact on survival is not required as long as the treating physician considers that treatment on study is appropriate for the subject and documents that the subject elects to defer the approved therapies\n* During the dose-escalation portion, patients must have primary liver malignancy (including hepatocellular carcinoma or cholangiocarcinoma) OR a solid tumor with liver dominant disease; liver dominant disease is defined as the majority of the tumor burden being in the liver per investigator assessment AND no more than two extrahepatic sites of disease (site of disease refers to organ or system). During the dose expansion portion of the study, eligibility may be limited to one or more tumor types depending on findings from the dose-escalation phase; this will be clarified in an amendment\n* Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Patient must have recovered from any toxic effects of previous chemotherapy, targeted therapy or radiotherapy as judged by the Investigator to =\\\u003C grade 1 (except for alopecia). Residual sensory neuropathy =\\\u003C grade 2 is allowed. Residual endocrine adverse events (such as hypothyroidism or hypoadrenalism) that are manageable with replacement therapy are allowed\n* Previous chemotherapy\u002Fradiotherapy\u002Ftargeted\u002Fimmunotherapy therapy should have been completed at least 4 weeks prior to start of AU409 administration, or five half-lives, whichever is shorter (except for palliative radiation therapy that should be completed \\>= 14 days prior to study entry)\n* Patients must have an estimated life expectancy of at least 3 months\n* Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation. A male participant must agree to use highly effective contraception during the intervention period and for 60 days after the last dose of AU409 and refrain from donating sperm during this period. WOCBP are eligible to participate if they are not pregnant, not breastfeeding, and agree to follow the contraceptive guidance during the study intervention period and for at least 90 days after the last dose of AU409\n\n  * Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n* A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: Has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)\n* Patients must agree, as part of the informed consent, to undergo liver biopsy (for a subset of patients enrolled at and above dose level 4) and to provide blood for pharmacokinetics analysis\n* Absolute neutrophil count (ANC) \\>= 1500\u002Fmm\\^3\n* Platelet count \\>= 100,000\u002Fmm\\^3\n* Hemoglobin \\>= 8 g\u002FdL (prior transfusion is allowed if completed 2 weeks prior to screening and hemoglobin remains \\>= 8 g\u002FdL)\n* For patients with HCC with splenic sequestration: ANC \\>= 1000\u002Fmm\\^3\n* For patients with HCC with splenic sequestration: Platelets \\>= 70,000\n* Calculated clearance \\>= 60 mL\u002Fmin\u002F1.73 m\\^2. Actual body weight should be used for calculating creatinine clearance (e.g., using the Cockroft-Gault formula). For subjects with a Body Mass Index (BMI) \\> 30 kg\u002Fm\\^2, lean body weight should be used instead\n* Total bilirubin =\\\u003C 1.5 X upper limit of normal (ULN) (subjects with known Gilbert's hepatic function disease can have bilirubin of up to 2 X ULN)\n* Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) =\\\u003C 3 X ULN; or AST\u002FALT =\\\u003C 5 X ULN if patient has liver tumors\n* Prothrombin time (PT)\u002Finternational normalized ratio (INR) =\\\u003C 1.8 times upper limit of normal (unless patient is on anticoagulation)\n\nExclusion Criteria:\n\n* Patients who have had hypersensitivity to pentamidine or any excipients of AU409\n* Treatment with other anticancer therapies (including surgery, radiation therapy, chemotherapy, anti-angiogenic therapy, targeted therapy, or radiofrequency ablation therapy, etc.) or investigational therapy within 28 days prior to study entry (except for palliative radiation therapy that should be completed \\>= 14 days prior to study entry)\n* Hepatocellular carcinoma patients with a Child Pugh score \\>= B7\n* Patients with known central nervous system metastases which are untreated or symptomatic; patients with treated brain metastases (completed \\>= 30 days prior to screening) are allowed provided they are asymptomatic and are off steroids\n* Patient with a history of the following within 6 months prior to cycle 1 day 1: a myocardial infarction, severe\u002Funstable angina pectoris, coronary\u002Fperipheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia, cerebrovascular accident, transient ischemic attack, or seizure disorder. Atrial fibrillation is allowed if rate is controlled\n* Patients who have corrected QT (QTc) interval to \\> 470 msec (Fredericia's equation) on 2 out of 3 electrocardiogram (ECG)'s (if first ECG has QTc \\\u003C 470, no need to repeat, if first ECG has QTc \\> 470 repeat twice for a total of 3 ECG's)\n* Patients who are on therapeutic anticoagulation with warfarin; however, patients on therapeutic doses of with low molecular weight heparins or Factor Xa inhibitors are eligible\n* Patient with history of gastrointestinal surgery or malabsorptive conditions that may change the absorption of drugs and\u002For cause rapid transit (such as total gastrectomy, small bowel resection, etc.)\n* Patients who have known active hepatitis B. Patients with chronic hepatitis B who are on anti-viral therapy and have a hepatitis B viral load of =\\\u003C 500 IU\u002FmL are allowed on the study. Patients with chronic Hepatitis C are allowed\n* Patients who have active infection requiring treatment (except hepatitis B and C as noted above) including known human immunodeficiency virus (HIV) infection\n* Patients who have concurrent conditions resulting in immune compromise, including chronic treatment with corticosteroids or other immunosuppressive agents\n* Patients who have any other condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results\n* Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants\n* Patients who are on medications that are considered to be strong inducers or inhibitors of the cytochrome P450 isoenzymes should have such medications discontinued or replaced. Such medications should be avoided for one week prior to first dose of treatment and during the trial participation. If these medications are absolutely necessary for the patient and cannot be replaced, enrollment may still be considered on a case by case basis if it is in the patient's best interest and after discussion with the principal investigator (PI)",{"count":549,"type":23},36,[62],"This phase I trial tests the safety, side effects, and best dose of a new intervention, AU409, in treating patients with primary liver cancers that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or advanced solid tumors that have spread to the liver (liver metastatic disease). AU409 may stop cancer from growing and spreading. This trial may help researchers determine if AU409 is safe and effective in treating patients with liver cancers and solid tumors with liver metastatic disease.",[553,554,555,556,557,558,559],"Advanced Cholangiocarcinoma","Advanced Hepatocellular Carcinoma","Advanced Malignant Solid Neoplasm","Metastatic Malignant Neoplasm in the Liver","Refractory Malignant Solid Neoplasm","Stage III Hepatocellular Carcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8",{"date":445,"type":40},{"date":562,"type":40},"2023-03-29",{"date":564,"type":23},"2028-03-29",{"name":46,"class":47},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":18,"minAge":143,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":575,"conditions":576,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":578,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":582,"locationsCount":48},"100356441","characterization-of-t-cell-repertoire-in-patients-with-acute-myeloid-leukemia-undergoing-donor-stem-cell-transplant-100356441","NCT03921047","Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant","Characterization of T-cell Repertoire in Patients With AML Undergoing HSCT Through Next-Generation Sequencing of T Cell Receptor Alpha (TCRA) and T Cell Receptor Beta (TCRB) Genes","Inclusion Criteria:\n\n* Diagnosis of AML scheduled to undergo HSCT at University of Southern California (USC)\n\nExclusion Criteria:\n\n* Inability to provide consent because of severe mental disorders\n* Donor unwilling to provide consent",{"count":574,"type":23},250,"This research trial studies characterization of T-cell repertoire through next-generation sequencing in patients with acute myeloid leukemia undergoing stem cell transplant. Characterizing T-cell repertoire may help to understand if immune system plays a significant role in high risk patients with acute myeloid leukemia.",[577],"Acute Myeloid Leukemia",{"date":373,"type":40},{"date":580,"type":40},"2018-04-12",{"date":379,"type":23},{"name":46,"class":47},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":18,"minAge":143,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":599,"locationsCount":258},"100329364","pharmacogenomics-of-asparaginase-induced-hepatotoxicity-100329364","NCT03568266","Pharmacogenomics of Asparaginase Induced Hepatotoxicity","Pharmacogenomics of Age-Specific, Asparaginase-Induced Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Newly diagnosed with acute lymphoblastic leukemia (ALL) - no prior treatment for ALL\n* Receiving asparaginase as part of the primary treatment regimen\n* Ability to understand and the willingness to sign a written informed consent\n* For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC)\n\nExclusion Criteria:\n\n* Patients who are unable to give informed consent",{"count":530,"type":23},"This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.",[593],"Acute Lymphoblastic Leukemia","2026-05-27",{"date":445,"type":40},{"date":597,"type":40},"2018-05-22",{"date":379,"type":23},{"name":46,"class":47},{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":18,"minAge":143,"maxAge":607,"enrollmentInfo":608,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":609,"conditions":610,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":710,"lastUpdatePostDateStruct":711,"startDateStruct":713,"completionDateStruct":715,"leadSponsor":716,"locationsCount":258},"100612878","social-health-activity-behaviors-and-quality-of-life-among-young-adult-cancer-survivors-100612878","NCT07259304","Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors","Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors: A Longitudinal Study","Inclusion Criteria:\n\n* Diagnosed and\u002For treated with cancer between ages 18-39 at USC hospitals.\n* Cancer types prototypical for adolescents and young adults (AYAs) and cancer stages I-III; select patients with stage IV disease may be eligible, with approval by the principal investigator (PI) and in consultation with the treating clinician.\n* Must be within three months of a de novo cancer diagnosis at recruitment and on\u002Findicated for curative therapy (any modality). Patients may continue on adjuvant therapy throughout duration of the study.\n* Patients must have anticipated survival of \\>1-year at time of diagnosis.\n\nExclusion Criteria:\n\n* Diagnosis of blood malignancies such as leukemias (these cancers have divergent treatment patterns of longer duration than other cancers and are more commonly pediatric cancers). Some early stage lymphomas with favorable prognoses may be eligible, with approval by the PI and in consultation with the treating clinician.\n* Primary language other than English or Spanish.\n* Inability to complete a survey and\u002For wear an accelerometer either per the patient or in consultation with the clinician's judgment.","39 Years",{"count":574,"type":23},"This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young adult cancer survivors. Researchers also hope to learn how social relationships change after a cancer diagnosis, and how these changes might impact important health behaviors. The information provided may help researchers learn more about better ways to support young cancer patients in the future through interventions that help maintain good social relationships and health levels of physical activity.",[611,371,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680,681,682,683,684,685,686,687,688,689,690,691,692,693,694,695,696,697,698,699,700,701,702,703,704,705,706,707,708,709],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Central Nervous System Neoplasm","Clinical Stage I Cutaneous Melanoma AJCC v8","Clinical Stage IA Cutaneous Melanoma AJCC v8","Clinical Stage IB Cutaneous Melanoma AJCC v8","Clinical Stage II Cutaneous Melanoma AJCC v8","Clinical Stage IIA Cutaneous Melanoma AJCC v8","Clinical Stage IIB Cutaneous Melanoma AJCC v8","Clinical Stage IIC Cutaneous Melanoma AJCC v8","Clinical Stage III Cutaneous Melanoma AJCC v8","Hodgkin Lymphoma","Malignant Bone Neoplasm","Malignant Brain Neoplasm","Malignant Solid Neoplasm","Malignant Testicular Neoplasm","Non-Hodgkin Lymphoma","Pathologic Stage I Cutaneous Melanoma AJCC v8","Pathologic Stage IA Cutaneous Melanoma AJCC v8","Pathologic Stage IB Cutaneous Melanoma AJCC v8","Pathologic Stage II Cutaneous Melanoma AJCC v8","Pathologic Stage IIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIC Cutaneous Melanoma AJCC v8","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Stage I Cervical Cancer AJCC v8","Stage I Colorectal Cancer AJCC v8","Stage I Differentiated Thyroid Gland Carcinoma AJCC v8","Stage I Ovarian Cancer AJCC v8","Stage I Thyroid Gland Medullary Carcinoma AJCC v8","Stage I Uterine Corpus Cancer AJCC v8","Stage IA Cervical Cancer AJCC v8","Stage IA Ovarian Cancer AJCC v8","Stage IA Uterine Corpus Cancer AJCC v8","Stage IA1 Cervical Cancer AJCC v8","Stage IA2 Cervical Cancer AJCC v8","Stage IB Cervical Cancer AJCC v8","Stage IB Ovarian Cancer AJCC v8","Stage IB Uterine Corpus Cancer AJCC v8","Stage IB1 Cervical Cancer AJCC v8","Stage IB2 Cervical Cancer AJCC v8","Stage IC Ovarian Cancer AJCC v8","Stage II Cervical Cancer AJCC v8","Stage II Colorectal Cancer AJCC v8","Stage II Differentiated Thyroid Gland Carcinoma AJCC v8","Stage II Ovarian Cancer AJCC v8","Stage II Thyroid Gland Medullary Carcinoma AJCC v8","Stage II Uterine Corpus Cancer AJCC v8","Stage IIA Cervical Cancer AJCC v8","Stage IIA Colorectal Cancer AJCC v8","Stage IIA Ovarian Cancer AJCC v8","Stage IIA1 Cervical Cancer AJCC v8","Stage IIA2 Cervical Cancer AJCC v8","Stage IIB Cervical Cancer AJCC v8","Stage IIB Colorectal Cancer AJCC v8","Stage IIB Ovarian Cancer AJCC v8","Stage IIC Colorectal Cancer AJCC v8","Stage III Cervical Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Differentiated Thyroid Gland Carcinoma AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Thyroid Gland Medullary Carcinoma AJCC v8","Stage III Uterine Corpus Cancer AJCC v8","Stage IIIA Cervical Cancer AJCC v8","Stage IIIA Colorectal Cancer AJCC v8","Stage IIIA Ovarian Cancer AJCC v8","Stage IIIA Uterine Corpus Cancer AJCC v8","Stage IIIA1 Ovarian Cancer AJCC v8","Stage IIIA2 Ovarian Cancer AJCC v8","Stage IIIB Cervical Cancer AJCC v8","Stage IIIB Colorectal Cancer AJCC v8","Stage IIIB Ovarian Cancer AJCC v8","Stage IIIB Uterine Corpus Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8","Stage IIIC Ovarian Cancer AJCC v8","Stage IIIC Uterine Corpus Cancer AJCC v8","Stage IIIC1 Uterine Corpus Cancer AJCC v8","Stage IIIC2 Uterine Corpus Cancer AJCC v8","2026-05-26",{"date":712,"type":40},"2026-05-28",{"date":714,"type":40},"2021-11-24",{"date":379,"type":23},{"name":46,"class":47},""]